Jaguar Health delays quarterly report, cites late data and transactions

What happened

Jaguar Health, Inc., a pharmaceutical company based in San Francisco, said on August 14, 2026, that it would not file its quarterly report for the quarter ended June 30, 2026, on time. The company filed a Form 12b-25 with the SEC, a notification of late filing, saying it needs more time to complete the report.

In the filing, Jaguar Health said it could not finish its quarterly report because of "a delay in obtaining and compiling information required to be included in the Form 10-Q including significant and material subsequent event transactions." The company said the delay could not be resolved without "unreasonable effort or expense."

The company's stock rose 16.99% on the day of the filing, closing at $0.916 per share, with trading volume of about 1.22 million shares, roughly 12 times its average volume. The price data does not explain why the stock moved.

Jaguar Health, Inc. develops prescription medicines for gastrointestinal conditions, according to its public filings. Its products include Mytesi, a treatment for diarrhea in HIV patients, and it is developing other drugs.

What the filing says

The Form 12b-25 says the company will file its Form 10-Q no later than the fifth calendar day after the prescribed due date. For a quarterly report, the SEC allows a five-day extension when a company files this notice.

The filing also states that Jaguar Health has filed all other required periodic reports in the preceding 12 months, and it says the company does not anticipate a significant change in results of operations from the same period last year.

The company listed Carol Lizak, its Chief Financial Officer, as the contact for the notification.

What this means

A Form 12b-25 is a notice a company files with the SEC when it cannot meet the deadline for a required report, such as a quarterly report on Form 10-Q. It is not an admission of wrongdoing; instead, it tells investors and regulators that the report will be late and explains why.

For a quarterly report, the prescribed deadline is 40 days after the end of the quarter. Jaguar Health's quarter ended June 30, 2026, so the original due date was August 10, 2026. By filing the 12b-25, the company gets up to five additional calendar days, meaning it must file the 10-Q by August 15, 2026.

The filing mentions "material subsequent event transactions" but does not identify what those transactions were. The company did not explain further in the filing, and the price data does not provide a reason for the stock's rise.

If the company fails to file the 10-Q even within the extension period, it could lose its ability to use a short-form registration statement for new securities offerings, a common consequence for late filers. The company's own filing warns that further delays could cause stock price volatility and loss of confidence in management.